Mankerious, NaderNaderMankeriousToelg, RalphRalphToelgAbdelghani, MohammadMohammadAbdelghaniGarcia-Garcia, Hector MHector MGarcia-GarciaFarhan, SerdarSerdarFarhanAllali, AbdelhakimAbdelhakimAllaliWindecker, StephanStephanWindeckerLefèvre, ThierryThierryLefèvreSaito, ShigeruShigeruSaitoKandzari, David EDavid EKandzariWaksman, RonRonWaksmanRichardt, GertGertRichardtHemetsberger, RayyanRayyanHemetsberger2025-01-302025-01-302025-01-04https://boris-portal.unibe.ch/handle/20.500.12422/202786Introduction And Objectives Patients undergoing percutaneous coronary intervention in vessels with moderate-to-severe tortuosity are at higher risk of adverse outcomes, but data are scarce in the era of newer-generation stents. We compared outcomes following percutaneous coronary intervention in vessels with moderate-to-severe tortuosity using a bioresorbable-polymer sirolimus-eluting stent (BP-SES) vs a durable-polymer everolimus-eluting stent. Methods A total of 2350 patients from the BIOFLOW II, IV, and V randomized trials were stratified into 2 groups based on target-vessel tortuosity: none-to-mild and moderate-to-severe. The primary endpoints included target lesion failure (TLF)-a composite of cardiac death, target-vessel myocardial infarction (TV-MI), or ischemia-driven target lesion revascularization (TLR)-and probable/definite stent thrombosis at 3 years. Results Patients with moderate-to-severe tortuosity (n = 903) had more comorbidities than those with none-to-mild tortuosity (n = 1447). Rates of TLF (P = .354), cardiac death (P = .690), TLR (P = .447), and stent thrombosis (P = .084) were similar between the 2 groups, whereas TV-MI occurred more frequently in the moderate-to-severe tortuosity group (P = .031). However, on multivariate analysis, moderate-to-severe tortuosity was not an independent predictor of TV-MI (adjusted HR, 1.06; 95% CI, 0.72-1.55; P = .772). Among patients with moderate-to-severe tortuosity, the use of BP-SES was associated with significantly lower rates of TLF compared with the durable-polymer everolimus-eluting stent (7.8% vs 13.4%; HR, 0.57; 95% CI, 0.37-0.87; P = .009), driven by reductions in TV-MI (5.0% vs 9.2%; HR, 0.54; 95% CI, 0.32-0.90; P = .018) and TLR (2.7% vs 6.1%; HR, 0.45; 95% CI, 0.23-0.90; P = .021). Conclusions This pooled analysis of the randomized BIOFLOW trials demonstrates that patients with none-to-mild and moderate-to-severe tortuosity have comparable long-term adverse event rates. However, the use of BP-SES in patients with moderate-to-severe tortuosity may help mitigate potential ischemic risks.Clinical Trial Registration Clinicaltrials.gov NCT01356888, NCT01939249, NCT02389946.enBIOFLOWCoronary tortuosityIntervención coronaria percutáneaNewer-generation drug-eluting stentOrsiroPercutaneous coronary interventionStents farmacoactivos de nueva generaciónTortuosidad coronariaXience600 - Technology::610 - Medicine & healtharticle10.48620/850433976174510.1016/j.rec.2024.12.009